RenovoRx Data Suggests Targeted Chemotherapy Approach May Reduce Side Effects
Event summary
- RenovoRx announced new pharmacokinetic (PK) and pharmacodynamic data from a sub-study of its Phase III TIGeR-PaC clinical trial, to be presented at ASCO GI 2026.
- The data indicates that RenovoRx’s TAMP therapy platform, combined with intra-arterial gemcitabine (IAG), resulted in reduced systemic gemcitabine levels and increased levels of its inactive metabolite.
- The sub-study evaluated 16 patients across six TIGeR-PaC clinical sites, comparing IAG to intravenous gemcitabine.
- The TIGeR-PaC trial aims to determine the impact of IAG on overall survival and secondary endpoints, including reduced side effects, and is currently enrolling.
The big picture
RenovoRx’s approach to targeted chemotherapy delivery represents a potential shift away from traditional systemic chemotherapy, which often carries significant side effects. The data presented suggests that localized drug delivery via the TAMP platform could improve efficacy while minimizing toxicity, a critical need in pancreatic cancer treatment, a market with significant unmet needs. Success hinges on demonstrating clinical benefit in the Phase III trial and securing regulatory approval.
What we're watching
- Clinical Validation
- The full Phase III TIGeR-PaC trial results will be critical to validate the observed PK/PD benefits and confirm whether IAG translates to improved overall survival and reduced side effects in a larger patient population.
- Regulatory Pathway
- The FDA’s evaluation of the IAG combination product under the 21 CFR 312 pathway will determine the speed and likelihood of potential approval, impacting RenovoRx’s commercialization timeline.
- Commercial Adoption
- The pace at which medical institutions adopt RenovoCath and IAG, beyond the initial purchase orders, will be a key indicator of the therapy’s long-term market viability and RenovoRx’s ability to scale its commercial operations.
Related topics